PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ACADIA Pharmaceuticals Inc. (ACAD)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0042251084
CUSIP004225108
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$2.93B
PEG Ratio-0.42
Total Revenue (TTM)$648.57M
Gross Profit (TTM)$593.11M
EBITDA (TTM)-$457.00K
Year Range$14.55 - $32.59
Target Price$27.32
Short %9.77%
Short Ratio7.69

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ACADIA Pharmaceuticals Inc.

Popular comparisons: ACAD vs. ABT, ACAD vs. TPR

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ACADIA Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


100.00%150.00%200.00%250.00%300.00%350.00%400.00%450.00%FebruaryMarchAprilMayJuneJuly
171.49%
395.48%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

ACADIA Pharmaceuticals Inc. had a return of -41.90% year-to-date (YTD) and -39.41% in the last 12 months. Over the past 10 years, ACADIA Pharmaceuticals Inc. had an annualized return of -1.25%, while the S&P 500 had an annualized return of 10.91%, indicating that ACADIA Pharmaceuticals Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-41.90%16.48%
1 month18.89%1.67%
6 months-35.38%14.21%
1 year-39.41%21.98%
5 years (annualized)-4.35%13.13%
10 years (annualized)-1.25%10.91%

Monthly Returns

The table below presents the monthly returns of ACAD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-17.25%-10.30%-20.44%-9.63%-9.63%7.62%-41.90%
202319.54%8.72%-9.04%13.34%10.17%1.91%22.09%-7.59%-22.87%8.30%-1.28%40.53%96.67%
2022-3.64%12.98%-4.68%-23.86%-12.42%-12.76%4.26%11.84%-0.43%-2.02%-2.81%2.18%-31.79%
2021-10.12%1.91%-47.31%-20.31%8.66%9.18%-11.32%-19.05%-5.14%8.07%6.96%21.56%-56.34%
2020-6.64%7.01%-1.15%14.34%2.84%-2.44%-14.24%-4.76%4.19%12.61%21.98%-5.65%24.96%
201940.88%16.33%1.32%-10.43%-0.25%11.42%-8.04%12.53%30.12%17.84%6.79%-5.54%164.56%
2018-0.66%-16.70%-9.81%-29.64%14.48%-15.64%-1.18%-5.77%45.99%-6.17%-2.16%-15.16%-46.30%
201719.94%10.18%-9.79%-0.15%-25.11%8.48%6.74%19.62%5.78%-7.54%-13.15%-0.46%4.40%
2016-41.96%-16.58%61.99%15.52%9.69%-8.38%14.11%-13.26%-1.00%-26.72%15.79%6.85%-19.10%
2015-4.16%24.78%-14.17%4.85%20.57%1.65%16.55%-24.95%-9.72%5.29%8.99%-6.06%12.28%
2014-6.76%21.46%-14.03%-17.26%2.58%9.39%-10.27%18.30%3.25%11.87%7.83%6.29%27.05%
201329.68%0.66%30.81%62.34%9.15%29.00%8.54%1.32%37.63%-17.27%2.49%7.30%437.42%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ACAD is 14, indicating that it is in the bottom 14% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ACAD is 1414
ACAD (ACADIA Pharmaceuticals Inc.)
The Sharpe Ratio Rank of ACAD is 1313Sharpe Ratio Rank
The Sortino Ratio Rank of ACAD is 1313Sortino Ratio Rank
The Omega Ratio Rank of ACAD is 1414Omega Ratio Rank
The Calmar Ratio Rank of ACAD is 1717Calmar Ratio Rank
The Martin Ratio Rank of ACAD is 1313Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ACAD
Sharpe ratio
The chart of Sharpe ratio for ACAD, currently valued at -0.72, compared to the broader market-2.00-1.000.001.002.003.00-0.72
Sortino ratio
The chart of Sortino ratio for ACAD, currently valued at -1.01, compared to the broader market-4.00-2.000.002.004.00-1.01
Omega ratio
The chart of Omega ratio for ACAD, currently valued at 0.87, compared to the broader market0.501.001.502.000.87
Calmar ratio
The chart of Calmar ratio for ACAD, currently valued at -0.55, compared to the broader market0.001.002.003.004.005.006.00-0.55
Martin ratio
The chart of Martin ratio for ACAD, currently valued at -1.26, compared to the broader market-30.00-20.00-10.000.0010.0020.00-1.26
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.99, compared to the broader market-2.00-1.000.001.002.003.001.99
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.81, compared to the broader market-4.00-2.000.002.004.002.81
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.35, compared to the broader market0.501.001.502.001.35
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.59, compared to the broader market0.001.002.003.004.005.006.001.59
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.44, compared to the broader market-30.00-20.00-10.000.0010.0020.007.44

Sharpe Ratio

The current ACADIA Pharmaceuticals Inc. Sharpe ratio is -0.72. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of ACADIA Pharmaceuticals Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00FebruaryMarchAprilMayJuneJuly
-0.72
1.99
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ACADIA Pharmaceuticals Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%FebruaryMarchAprilMayJuneJuly
-68.09%
-1.97%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ACADIA Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ACADIA Pharmaceuticals Inc. was 96.29%, occurring on Nov 12, 2010. Recovery took 645 trading sessions.

The current ACADIA Pharmaceuticals Inc. drawdown is 68.09%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.29%Mar 17, 20061175Nov 12, 2010645Jun 10, 20131820
-77.18%Jul 8, 2020493Jun 21, 2022
-73.99%Jul 20, 2015777Aug 17, 2018327Dec 5, 20191104
-40.8%Feb 28, 201432Apr 14, 2014161Dec 2, 2014193
-38.42%Dec 9, 201967Mar 16, 202029Apr 27, 202096

Volatility

Volatility Chart

The current ACADIA Pharmaceuticals Inc. volatility is 10.78%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%FebruaryMarchAprilMayJuneJuly
10.78%
2.94%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ACADIA Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

P/E Ratio

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for ACADIA Pharmaceuticals Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items